Clinical Trials
7 trialsNCT06590558 2025-07-03
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04826016 2023-03-20
POLTER
MedSIR
Phase 1/2 Withdrawn
NCT03637868 2020-05-06
ERIBRAIN
Institut Paoli-Calmettes
Phase 2 Withdrawn
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT02215876 2016-04-15
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT02396433 2015-08-25
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
The University of Texas Health Science Center at San Antonio
Phase 1/2 Withdrawn